{
    "clinical_study": {
        "@rank": "31845", 
        "arm_group": [
            {
                "arm_group_label": "Neoral", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients who continued to be treated with the drug Neoral."
            }, 
            {
                "arm_group_label": "Gengraf arm", 
                "arm_group_type": "Experimental", 
                "description": "Patients were randomly selected to be converted to 'Gengraf\u00ae capsule containing 25mg or 100mg cyclosporine'"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to establish the therapeutic equivalence of Gengraf\u00ae with the\n      standard treatment Neoral\u00ae for a treatment period of 6 months in stable renal allograft\n      transplant recipients with respect to drug levels, dosage, and acute graft rejection and\n      other adverse events."
        }, 
        "brief_title": "Gengraf Conversion Study in Stable Renal Allograft Transplant Recipients", 
        "completion_date": {
            "#text": "May 2006", 
            "@type": "Actual"
        }, 
        "condition": "End Stage Renal Failure", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Failure, Chronic", 
                "Renal Insufficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "The introduction of cyclosporine (CsA) into clinical practice resulted in improvements in\n      acute renal allograft rejection rate and graft survival in renal transplant patients.\n      Gengraf a microemulsion formulation of CsA though granted an AB-rated equivalent to Neoral,\n      because of concerns over the use of generic drugs in transplantation, we undertook this\n      study to evaluate the clinical efficacy and safety of Gengraf.\n\n      We conducted a multicenter, randomized, open labeled study to establish the equivalence\n      between Gengraf and Neoral in stable renal transplant recipients for a treatment period of 6\n      months. 6 months post transplant patients with stable graft function and receiving a stable\n      dose of neoral were recruited into the study. Eligible patients were randomly assigned to\n      remain on Neoral or convert to an equal milligram-for-milligram dose of Gengraf. The primary\n      end-point was serum creatinine at 26 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Written informed consent obtained from patient or parents/guardian.\n\n          2. Patients who are more than 6 months post transplant\n\n          3. Stable graft function i.e. serum creatinine less than 300 umol/l\n\n          4. Patients currently on a stable dose of capsule Neoral within last one month\n\n        Exclusion Criteria:\n\n          1. Multiple organ transplantation\n\n          2. Pregnant or nursing woman, or women of childbearing potential without an effective\n             method of birth control. Effective birth control methods are oral contraception,\n             Norplant, surgical sterilization, Intra Uterine Device or diaphragms in conjunction\n             with spermicidal foam and condom on the male partner.\n\n          3. Participation in any drug trial in which the patient received an investigational drug\n             within 30 days preceding the screening phase of this study.\n\n          4. Those persons directly involved in the conduct of the study.\n\n          5. Active infection at the time of screening for enrollment into trial.\n\n          6. Acute graft rejection within the past 3 months\n\n          7. Mentally unstable or history of mental diseases\n\n          8. History of drug or alcohol abuse within the past 2 years.\n\n          9. History of non-compliance to medical regimen and patients who are unwilling or unable\n             to comply with the protocol.\n\n         10. Decompensated liver disease\n\n         11. Any serious medical conditions or disability, which in the opinion of the\n             investigator, would interfere with treatment or assessment or preclude completion of\n             this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "106", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 4, 2010", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01990118", 
            "org_study_id": "15.041"
        }, 
        "intervention": [
            {
                "arm_group_label": "Neoral", 
                "description": "Neoral\u00ae capsule containing 25mg or 100mg cyclosporine", 
                "intervention_name": "Neoral", 
                "intervention_type": "Drug", 
                "other_name": "Cyclosporine"
            }, 
            {
                "arm_group_label": "Gengraf arm", 
                "description": "Transplant patients who were stable on Neoral were converted to Gengraf", 
                "intervention_name": "Gengraf\u00ae capsule containing 25mg or 100mg cyclosporine", 
                "intervention_type": "Drug", 
                "other_name": "Generic Cyclosporine"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Cyclosporine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Renal transplant", 
            "Renal allograft rejection", 
            "Cyclosporine", 
            "Gengraf"
        ], 
        "lastchanged_date": "November 15, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "George Town", 
                    "country": "Malaysia", 
                    "state": "Penang", 
                    "zip": "10990"
                }, 
                "name": "Clinical Research Centre, Penang Hospital"
            }
        }, 
        "location_countries": {
            "country": "Malaysia"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Multi-center, Open Label Trial to Establish the Therapeutic Equivalence Between Neoral\u00ae and Gengraf\u00ae in Stable Renal Allograft Recipients [Gengraf Conversion Study]", 
        "overall_official": {
            "affiliation": "Penang Hospital, Ministry of Health Malaysia", 
            "last_name": "Dr.Ong L Meng, MBBS, FRCP", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Malaysia: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Serum creatinine level at 12 weeks after conversion from Neoral to Gengraf", 
            "measure": "Serum creatinine level at 12 weeks", 
            "safety_issue": "No", 
            "time_frame": "at 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01990118"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Penang Hospital, Malaysia", 
            "investigator_full_name": "Dr.Ong Loke Meng", 
            "investigator_title": "Consultant Nephrologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "CsA trough concentration and at 2 hour after CsA administration, at 2 weeks, 6 weeks 12 weeks, 6 months, 9 months and 12 months post randomization.", 
            "safety_issue": "No", 
            "time_frame": "weeks 2, 6, 12, months 6, 9 and 12."
        }, 
        "source": "Penang Hospital, Malaysia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Penang Hospital, Malaysia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2004", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}